Pharma Business review is using cookies

ContinueLearn More
October 18, 2018

Diurnal puts hold on US development of adrenal drug Chronocort

Diurnal Group has decided to put a hold on all activities relating to the US development of its adrenal drug Chronocort following a failure in a recently concluded phase 3 trial in adults with congenital adrenal hyperplasia (CAH).

Image: Diurnal will suspend the US development of adrenal drug Chronocort. Photo: courtesy of jk1991 /